Enlivex Ltd. Ordinary Shares (ENLV) Stock Price

ENLVStock
$0.20−98.75%52W
Market Cap$4.08M
P/E0.00x
PEG Ratio—
Div yield—
Beta1.53

ENLV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-108.23%
Price vs S&P 500 (4W)-69.08%
VGM Score50.99
P/E Ratio (Annual)0.00x

ENLV Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.31$97.80+31648.39%(+$98.11)
Q4 2025-$0.45-$1.41-212.70%(-$0.96)
Q3 2025-$1.80-$1.35+25.00%(+$0.45)
Q2 2025-$2.40-$1.20+50.00%(+$1.20)
Q1 2025-$2.40-$2.25+6.25%(+$0.15)

ENLV Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ENLVEnlivex Ltd. Ordinary Shares
A—F————$0.20
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Enlivex Ltd. Ordinary Shares

Enlivex Ltd is a clinical-stage immunotherapy company developing Allocetra, a macrophage reprogramming therapy for osteoarthritis currently in late-stage clinical development. The company's platform leverages immune cell reprogramming technology to address degenerative joint disease.